Market Currents
Jazz Pharmaceuticals (JAZZ) gains 3.1% AH after guiding for 2012 revenue of $465M-$490M and EPS...
-
Thursday, January 5, 2012, 4:22 PM ETJazz Pharmaceuticals (JAZZ) gains 3.1% AH after guiding for 2012 revenue of $465M-$490M and EPS of $4-$4.15, above a consensus of $462.8M and $3.40. The guidance takes into account Jazz's planned merger with Azur Pharma, which the companies hope to close on Jan. 16 - it's possible not all analyst forecasts took the deal into account.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
